HR 1108

Recall Unsafe Drugs Act of 2017

Congress: 115 (2017–2019, Ended)
Chamber: House
Policy Area: Health
Introduced: Feb 16, 2017
Current Status: Referred to the Subcommittee on Digital Commerce and Consumer Protection.
Latest Action: Referred to the Subcommittee on Digital Commerce and Consumer Protection. (Feb 17, 2017)
Official Text: https://www.congress.gov/bill/115th-congress/house-bill/1108

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]
Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Mar 8, 2017
Rep. Langevin, James R. [D-RI-2]	D · RI		Mar 8, 2017
Rep. Raskin, Jamie [D-MD-8]	D · MD		Mar 8, 2017
Rep. Slaughter, Louise McIntosh [D-NY-25]	D · NY		Oct 25, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Feb 17, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Feb 16, 2017)

Recall Unsafe Drugs Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to require producers of medications to notify the Food and Drug Administration (FDA) of the identity and location of a medication if the producer has reason to believe: (1) that the medication is adulterated or misbranded; and (2) there is a reasonable probability that the use or consumption of, or exposure to, the medication will cause a threat of serious adverse health consequences or death to humans or animals.

The FDA may: (1) request that the distributor of a medication that is in violation of the FFDCA voluntarily recall the medication; (2) require the distributor of a medication that may cause serious adverse health consequences to immediately cease distribution of the medication; (3) recall a medication for which distribution has been ceased after giving the distributor an opportunity for an informal hearing; and (4) immediately recall a medication that presents an imminent threat of serious adverse health consequences. Distributors may appeal these FDA orders.

In the case of a recall, the FDA must notify consumers and state and local health officials to whom the medication was, or may have been, distributed.

Medication distributors must have a recall plan in effect.

Actions Timeline

- **Feb 17, 2017:** Referred to the Subcommittee on Digital Commerce and Consumer Protection.
- **Feb 16, 2017:** Introduced in House
- **Feb 16, 2017:** Referred to the House Committee on Energy and Commerce.